Yinying Y. Lu

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 105 publications

Consensus on standardized later-line systemic therapy for hepatocellular carcinoma.

Consensus on standardized later-line systemic therapy for hepatocellular carcinoma.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: May 11, 2026

A Single‑Center Retrospective Cohort Study: Impact of Glycemic Control on First‑Line TKI Plus PD‑1 Inhibitors versus TKI Alone in Intermediate‑to‑advanced Unresectable Hepatocellular Carcinoma(HCC) with Type 2 Diabetes Mellitus (T2DM).

A Single‑Center Retrospective Cohort Study: Impact of Glycemic Control on First‑Line TKI Plus PD‑1 Inhibitors versus TKI Alone in Intermediate‑to‑advanced Unresectable Hepatocellular Carcinoma(HCC) with Type 2 Diabetes Mellitus (T2DM).

Journal: Journal of hepatocellular carcinoma

Published: April 24, 2026

Research progress on immune tolerance mechanisms in liver metastatic tumors and the "Liver-metastasis-oriented shared-mechanism therapeutic strategy" approach.

Research progress on immune tolerance mechanisms in liver metastatic tumors and the "Liver-metastasis-oriented shared-mechanism therapeutic strategy" approach.

Journal: Medical review (2021)

Published: November 18, 2025

Low-level HBV viremia independently predicts poor outcomes in patients with intermediate-to-advanced HBV-related hepatocellular carcinoma receiving systemic therapy: a multicenter retrospective study.

Low-level HBV viremia independently predicts poor outcomes in patients with intermediate-to-advanced HBV-related hepatocellular carcinoma receiving systemic therapy: a multicenter retrospective study.

Journal: Therapeutic advances in medical oncology

Published: October 28, 2025

Predicting the Occurrence of Cachexia in Patients with BCLC Stage B/C Hepatocellular Carcinoma Receiving Systemic Therapy: A Nomogram Based on Common Clinical Parameters.

Predicting the Occurrence of Cachexia in Patients with BCLC Stage B/C Hepatocellular Carcinoma Receiving Systemic Therapy: A Nomogram Based on Common Clinical Parameters.

Journal: Journal of hepatocellular carcinoma

Published: August 21, 2025

Convergent systemic therapy for liver metastases: Bridging primary tumor heterogeneity through shared pathways.

Convergent systemic therapy for liver metastases: Bridging primary tumor heterogeneity through shared pathways.

Journal: iLIVER

Published: June 18, 2025

A Multicenter Retrospective Study: Impact of First-Line Treatment Strategies on second-Line Efficacy and Safety of Regorafenib with or Without PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma.

A Multicenter Retrospective Study: Impact of First-Line Treatment Strategies on second-Line Efficacy and Safety of Regorafenib with or Without PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma.

Journal: Journal of hepatocellular carcinoma

Published: May 07, 2025

Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.

Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.

Journal: European journal of medical research

Published: May 06, 2025

Phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors.

Phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors.

Journal: Journal for immunotherapy of cancer

Published: April 25, 2025

Impact of B18R-Encoding Messenger Ribonucleic Acid Co-Delivery on Neutralizing Antibody Production in Self-Amplifying Messenger Ribonucleic Acid Vaccines.

Impact of B18R-Encoding Messenger Ribonucleic Acid Co-Delivery on Neutralizing Antibody Production in Self-Amplifying Messenger Ribonucleic Acid Vaccines.

Journal: Vaccines

Published: March 27, 2025

Practice revolution in local interventional therapy for liver metastases.

Practice revolution in local interventional therapy for liver metastases.

Journal: iLIVER

Published: March 06, 2025

HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study.

HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study.

Journal: Scientific reports

Published: February 07, 2025

Showing 1-12 of 105

Last Updated: 09/26/2026